AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceNamed GroupsHealth CareGeographicals
Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousTreatment OutcomeRetrospective StudiesTissue DonorsGraft vs Leukemia EffectLeukemiaMyeloablative AgonistsChimerismHistocompatibilityHematologic DiseasesHistocompatibility TestingBusulfanTransplantation ChimeraMycosesWhole-Body IrradiationHepatic Veno-Occlusive DiseaseVidarabineRecurrenceCytomegalovirus InfectionsAspergillosisCord Blood Stem Cell TransplantationGraft vs Tumor EffectAntilymphocyte SerumSurvival AnalysisSiblingsPeripheral Blood Stem Cell TransplantationDonor SelectionSevere Combined ImmunodeficiencyLeukemia, Myeloid, AcuteBone Marrow TransplantationImmunocompromised HostLymphoproliferative DisordersAcute DiseaseStem Cell TransplantationMyelodysplastic SyndromesTime FactorsEuropeFollow-Up StudiesLymphohistiocytosis, HemophagocyticBronchiolitis ObliteransTransplantationSurvival RateImmunosuppressive AgentsHLA AntigensOpportunistic InfectionsPrecursor Cell Lymphoblastic Leukemia-LymphomaGraft SurvivalDisease-Free SurvivalAnemia, AplasticRisk FactorsRemission InductionCytomegalovirusCystitisEnzyme Replacement TherapyThermometryTransplantation ImmunologyLymphocyte DepletionT-LymphocytesStomatitisCombined Modality TherapyImmunosuppressionSurvivorsMediterranean RegionNeoplasmsProspective StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCyclophosphamideRoseolovirus InfectionsReceptors, KIRGanciclovirPlatelet TransfusionAntifungal AgentsCohort StudiesAdjustment DisordersMucositisBK VirusLeukemia, MyeloidIncidenceSalvage TherapyHemoglobinopathiesAntiviral AgentsPrognosisMinor Histocompatibility AntigensOrgan TransplantationAutoimmune DiseasesIron OverloadNeutropeniaPolyomavirus InfectionsVirus ActivationTransplantation, IsogeneicAdenovirus Infections, HumanEpstein-Barr Virus InfectionsLiving DonorsLung Diseases, FungalAdenoviridae Infections
TransplantationChemotherapyUnderwentHematopoietic stem cellGVHDComplete remissionAllogenicAcutePeripheral bloodRelapseTransplantAutologousPediatric2019Diagnosis2020SurvivalComplicationsRecipientsMultiple sclerosisHematologicalInfectionRelapsed or refractoryTrialsRadiotherapyTherapyUndergoOutcomesBoneClinicallyUndergonePrognosisMedian ageParticipantsProphylaxisDonorLymphomaSickle cell diMalignantTherapeuticsInvestigatorsMultidisciplinaryCancersRegimenUnmetMortalityAdultsGraftMethods2021YearsKEYTRUDAAdult patientsSeverely immunocompromised patientsAdverseImplicationsStem cellsDiseaseMalignancy
Transplantation39
Chemotherapy26
  • Immediately before an HSCT procedure, a patient receives chemotherapy. (wikipedia.org)
  • Hepatic VOD can occur in people who receive chemotherapy and HSCT. (wikipedia.org)
  • Patients in Europe with MSI-H/dMMR colorectal cancer have had only chemotherapy-containing regimens available to them in the first-line treatment setting and have historically faced poor outcomes," said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. (merck.com)
  • Patients received a median of 3(range: 2-6) prior chemotherapy regimens (exclusive of tositumomab/iodine-131tositumomab) before or after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • The mediannumber of chemotherapy regimens was 2 after tositumomab/iodine-131 tositumomaband prior to HSCT (range: 1-4). (cancernetwork.com)
  • Furthermore, with ATRA-ATO combinations, chemotherapy may safely be omitted in low-risk patients. (nature.com)
  • In the past two decades, therapy for newly diagnosed APL has evolved from an all- trans retinoic acid (ATRA)+chemotherapy backbone for all patients to the addition of arsenic trioxide (ATO) to ATRA with omission of chemotherapy in low-risk patients as a new standard of care. (nature.com)
  • Infections include hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with haematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy. (pharmaceutical-technology.com)
  • The blood cells are harvested from the donor and stored, and then the sickle cell disease patient is given high doses of chemotherapy to get rid of all the remaining blood cells in the bone marrow in order for them to be able to receive the healthy donated cells. (reachmd.com)
  • HSCT is the type of stem cell therapy in which a patient's existing immune system is completely eradicated through the use of powerful chemotherapy drugs and is then rebooted via an infusion of their own stem cells. (wheelchairkamikaze.com)
  • The myeloblative protocol uses a combination of very strong chemotherapy drugs to completely ablate (a fancy word for "destroy") patients' immune systems as well as their bone marrow (immune system cells are manufactured in the bone marrow). (wheelchairkamikaze.com)
  • Non-myeloblative HSCT uses a gentler chemotherapy regimen that takes down the immune system but leaves bone marrow intact. (wheelchairkamikaze.com)
  • The patients more vulnerable to COVID-19 disease are those suffering from lymphoma, leukemia, or myeloma, those with ongoing radical radiotherapy for lung cancer, immunotherapy, cytotoxic chemotherapy, protein kinase inhibitors, antibodies, or poly ADP ribose polymerase (PARP) inhibitors. (researchdive.com)
  • At the study's final analysis, there was not an improvement in OS for patients treated with KEYTRUDA plus LENVIMA with chemotherapy compared to KEYTRUDA with chemotherapy. (streetinsider.com)
  • There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. (oncotarget.com)
  • Background: Early antibiotic discontinuation has been advocated in haematology patients with fever of unknown origin during chemotherapy-induced neutropenia, but its safety is unknown. (amsterdamumc.org)
  • Constipation in patients with cancer is often secondary to drugs that are given to control other chemotherapy, or due to cancer-induced symptoms (such as anti-emetics for nausea and vomiting and opiods for pain) rather than to the chemotherapeutic agents themselves. (scot.nhs.uk)
  • Patient / carer information is central to the management of SACT-induced diarrhoea, including the possible causes (infection or chemotherapy side effect) and the potential for life threatening dehydration, particularly in babies and young children. (scot.nhs.uk)
  • Before starting chemotherapy patients and/or parents should be informed that diarrhoea may occur and what action to take should it do so (see Appendix 2). (scot.nhs.uk)
  • The trial met its primary endpoint, showing superior overall survival (OS) with Opdivo plus Yervoy versus chemotherapy (pemetrexed and cisplatin or carboplatin) in all randomized patients. (pharmiweb.com)
  • In the CheckMate -743 trial, this dual immunotherapy combination demonstrated a clinically meaningful improvement in survival over the standard of care, with 41% of patients who received Opdivo plus Yervoy still alive at two years, compared to only 27% with chemotherapy," said Abderrahim Oukessou, M.D., vice president, thoracic cancers development lead, Bristol Myers Squibb. (pharmiweb.com)
  • Of the patients who responded to Opdivo plus Yervoy , 32% had ongoing responses at two years (vs. 8% of chemotherapy responders). (pharmiweb.com)
  • Patients aged 60 years and older who were newly diagnosed with acute myeloid leukaemia and had not yet been treated were enrolled if they had an Eastern Cooperative Oncology Group performance status of 2 or less and were eligible for intensive chemotherapy. (bvsalud.org)
  • Patients were randomly assigned (1:1) to receive decitabine or standard chemotherapy (known as 3â +â 7). (bvsalud.org)
  • INTERPRETATION: 10-day decitabine did not improve overall survival but showed a better safety profile compared with 3â +â 7 chemotherapy in older patients with acute myeloid leukaemia eligible for intensive chemotherapy. (bvsalud.org)
  • Most patients up to the age of approximately 75 years should be considered for intensive combination chemotherapy with the aim to induce complete remission. (cancercentrum.se)
Underwent4
  • Twenty-eight children with de novo MDS who underwent allo-HSCT between 2011 and 2020 were enrolled. (nih.gov)
  • The review found that, for the majority of patients who underwent HSCT and developed treatment-related complications, rehabilitation exercises had a positive impact on their overall quality of life. (emerald.com)
  • For the study, the investigators conducted a retrospective analysis of clinical data from patients who underwent a HSCT between January 2010 and December 2016 at the Salvador Zubirán National Institute of Health Sciences and Nutrition. (contagionlive.com)
  • The final sample consisted of 35 records patients aged between 2 and 18 years old who underwent HSCT from February 2008 to December 2015 and who presented the data necessary for the study. (bvsalud.org)
Hematopoietic stem cell5
  • Hematopoietic stem cell transplant (HSCT) patients can suffer from long-term transplant-related complications that affect their quality of life and daily activities. (emerald.com)
  • The report also includes clinical guidance for adults who have received 7-valent PCV (PCV7) only and adults who are hematopoietic stem cell transplant recipients. (cdc.gov)
  • University of Michigan Comprehensive Cancer Center professor of internal medicine Daniel Couriel said prophylaxis against invasive Aspergillus and Candida infections play a major role in the management of severely immunocompromised patients with haematologic malignancies or hematopoietic stem cell transplant recipients at high-risk for these life-threatening fungal infections. (pharmaceutical-technology.com)
  • Various XSCID gene therapy clinical trials have been conducted over 20 years, both as an alternative to hematopoietic stem cell transplant (HSCT) or following a poor outcome. (stjude.org)
  • Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. (contagionlive.com)
GVHD12
  • HSCT survivor with active hepatitis B or C HSCT survivor on any TKI for either Philadelphia chromosome positive cancers or for GVHD treatments or for any other indication (e.g., imatinib for GIST, sorafenib for FLT3+ AML etc. (mayo.edu)
  • 1 The study enrolled 333 patients who were randomly assigned in a 1:1 ratio to one of two treatment groups receiving either an intravenous infusion of vedolizumab 300 mg or placebo on days -1 (before allo-HSCT), and on days +13, +41, +69, +97, +125, and +153 following allo-HSCT, alongside a background GvHD prophylaxis regimen. (businesswire.com)
  • Despite prophylactic treatment of the patients with immunosuppressive drugs after allo-HSCT, GvHD is still associated with non-relapse mortality (NRM) and contributes around 25% of NRM. (frontiersin.org)
  • Eight patients from the first NGFR-HSV-TK-studies developed acute ( n = 6) or chronic GvHD ( n = 2), which resolved after treatment with GCV alone in seven of eight patients. (frontiersin.org)
  • To date, no standard treatment is established for GVHD and no therapies are FDA approved for this indication in pediatric or adult patients. (oncologynurseadvisor.com)
  • Recent studies are investigating the efficacy of rituximab (Rituxan) for GVHD in pediatric HSCT patients. (oncologynurseadvisor.com)
  • Although not a first-line treatment for GVHD, rituximab may offer an alternative treatment option for GVHD in pediatric patients. (oncologynurseadvisor.com)
  • Acute Graft-versus-host disease (GvHD), one of the major complications of HSCT, is correlated to conditioning-induced gut barrier damage and may be predicted by pre-transplant serum citrulline level (Rashidi, BBMT 2018). (confex.com)
  • The trail was also carried out on patients who had undergone HSCT and were receiving immunosuppressive therapy for prevention or treatment of GVHD. (pharmaceutical-technology.com)
  • Their ongoing Phase 2 study is evaluating whether infusion of mesenchymal stem cells (MSCs) can treat steroid-resistant acute graft-versus-host disease (GVHD) or poor graft function after HSCT. (drugdiscoverynews.com)
  • GVHD, which is common among allogenic HSCT and rare in autologous HSCT, can be acute or chronic. (drugdiscoverynews.com)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
Complete remission1
  • With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
Allogenic2
  • this is used in both autologous and allogenic HSCT. (bdbiosciences.com)
  • of these, 53 percent are autologous (taken from the patient) and 47 percent are allogenic (taken from a donor other than the patient). (drugdiscoverynews.com)
Acute8
  • Twenty patients with aMDS had received pre-transplant treatment (three were treated with decitabine alone, thirteen with DAC + MMR, and four with acute myeloid leukemia type [AML-type] induction therapy). (nih.gov)
  • Although outcomes of children and adolescents with newly diagnosed acute myeloid leukemia (AML) have improved significantly over the past two decades, more than one-third of patients continue to relapse and experience suboptimal long-term outcomes. (haematologica.org)
  • As you probably know, the number of HSCT procedures for patients with acute leukemia continues to grow. (ebmt.org)
  • The approval is based on a non-comparative, multicentre trial designed to assess the pharmacokinetic properties, safety and tolerability of the tablets in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who had developed or were anticipated to develop significant neutropenia. (pharmaceutical-technology.com)
  • Nearly half of adult AML patients exhibit a cytogenetic normal acute myeloid leukemia (CN-AML). (biomedcentral.com)
  • Among the conditions HSCT can treat are: acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin lymphoma, Hodgkin disease, aplastic anemia and pure red-cell aplasia-but this list is not exhaustive. (drugdiscoverynews.com)
  • Clolar ® is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. (guidelinecentral.com)
  • Patients with acute promyelocytic leukemia (APL) are treated according to a separate protocol (included in the care program) based on all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). (cancercentrum.se)
Peripheral blood4
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Further, the HSCT was peripheral blood in 83 patients, bone marrow in 21, and primed-bone marrow in 21 patients. (contagionlive.com)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
Relapse9
  • Given the small numbers of patients with relapsed AML and historical logistical barriers to international collaboration including poor trial funding and drug availability, the management of AML relapse has varied among pediatric oncology cooperative groups with several salvage regimens utilized and a lack of universally defined response criteria. (haematologica.org)
  • While these measures have improved event-free survival (EFS) for children and adolescents/young adults with de novo AML, 30-40% of patients ultimately relapse. (haematologica.org)
  • Management of patients in first relapse has varied among pediatric oncology consortia with no universally agreed-upon standard of care at this time. (haematologica.org)
  • The Children's Oncology Group (COG) in North America, Ireland, New Zealand, and Australia and other cooperative groups have viewed relapse as an opportunity to test novel therapeutic agents efficiently in smaller cohorts of patients via early-phase clinical trials. (haematologica.org)
  • Finally, patients with a first relapse of AML (without or with prior HSCT) clearly represent a different disease population from patients with primary chemorefractory disease or from those in second or greater relapse who collectively experience highly different outcomes. (haematologica.org)
  • This increase is accompanied by improving results, due to both lower risk of relapse (maintenance therapy post HSCT, but also better disease control prior to HSCT), and decreased non-relapse mortality. (ebmt.org)
  • Those who received transplants had a 74% lower risk of relapse versus alemtuzumab, and a 66% lower risk of new MS activity detected via MRI. (medscape.com)
  • Compared with ocrelizumab, patients who received stem cell transplants had a 60% lower risk of relapse but the same risk of MS activity detected via MRI. (medscape.com)
  • Allo-hSCT is estimated to reduce the risk of leukemia relapse to half, but with significant risk for treatment-related complications. (cancercentrum.se)
Transplant19
  • Centre Hospitalier stem cell transplant (HSCT), are at high risk for PCP ( 5 - 8 ). (cdc.gov)
  • Lower GI aGvHD represents a critical unmet need in patients undergoing allo-HSCT," said Yi-Bin Chen, MD, Director, Hematopoietic Cell Transplant & Cell Therapy Program, Mass General Cancer Center. (businesswire.com)
  • Several studies are analyzing the effectiveness of rituximab in improving morbidity and mortality in pediatric transplant patients. (oncologynurseadvisor.com)
  • Patients were divided into subgroups (refractory cytopenia of childhood [RCC] and advanced MDS [aMDS]) and treated by HSCT alone or pre-transplant combination treatment based on risk stratification. (nih.gov)
  • Should healthcare organisations offer ongoing rehabilitation services for patients undergoing haematopoietic cell transplant? (emerald.com)
  • And it's really best to consult a transplant expert to evaluate which is best for a particular patient. (reachmd.com)
  • The CHMP recommended granting a conditional marketing authorisation for the ATMP Zalmoxis as an adjunctive, or add-on, treatment for adult patients receiving a haploidentical haematopoietic stem cell transplant (HSCT) for types of blood cancer to aid immune reconstitution and reduce the risk of graft-versus-host disease. (europa.eu)
  • however, it falls to 60 to 75% with other types of transplant, with over 50% of these patients requiring lifelong intravenous immunoglobulin therapy. (stjude.org)
  • A patient who had a recent bone marrow or stem cell transplant are also susceptible to the pandemic. (researchdive.com)
  • Aims Pharmacokinetics of tacrolimus after sublingual administration is not characterized in paediatric liver transplant patients. (unav.edu)
  • Compared to sedated patients, nonsedated status showed an increased first-order absorption rate constant (1.1 vs. 0.1 h(-1)) and a 24% reduction in bioavailability (F-NS) at 14 days post-transplant. (unav.edu)
  • A stem cell transplant reversed a debilitating neurological disease that causes half of the patients to go blind and lose the ability to walk five years after diagnosis. (northwestern.edu)
  • Most of the patients stayed better five years after the transplant and were able to avoid drug treatment that cost up to $500,000 yearly, reports a new study from Northwestern Medicine and Mayo Clinic. (northwestern.edu)
  • After the stem cell transplant, patients no longer had discernable AQP4 in their blood. (northwestern.edu)
  • The transplant improved patients' neurological disability and quality of life. (northwestern.edu)
  • In the trial, 12 patients with neuromyelitis optica received the stem cell transplant. (northwestern.edu)
  • Prior to the transplant, all patients were evaluated with tuberculin skin tests and chest x-ray. (contagionlive.com)
  • A trial looking at the effectiveness of a treatment made from donated stool samples to see if gut bacteria can be increased in patients having a transplant for blood cancer. (who.int)
  • Your doctor will probably tell you to start taking letermovir after your receive the transplant and to stop taking the medication 100 days after the transplant. (medlineplus.gov)
Autologous2
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • In the analysis, the investigators included 200 patients made up of 63 allogeneic-HSCT recipients, 74 autologous-HSCT recipients, and 63 HSCT donors. (contagionlive.com)
Pediatric5
  • However, the study authors noted that the project plan could be adapted for other pediatric patients that have a prolonged hospital stay, including pediatric oncology patients. (oncnursingnews.com)
  • This review provides a comprehensive overview of progress achieved to date in the treatment of pediatric patients with relapsed AML and highlights modern, state-of-the-art therapeutic approaches under active and emerging clinical investigation that have been facilitated by international collaboration among academic pediatric oncologists, laboratory scientists, regulatory agencies, pharmaceutical partners, cancer research sponsors, and patient advocates. (haematologica.org)
  • Response criteria for pediatric patients with relapsed AML have also not yet been standardized across study groups, although efforts to do this are currently underway. (haematologica.org)
  • KEYTRUDA is approved for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (businesswire.com)
  • The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established. (businesswire.com)
20196
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • KEYTRUDA was also granted accelerated approval in September 2019, and received full approval in July 2021, in combination with LENVIMA ® (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. (businesswire.com)
  • In January 2019, Burt published a randomized study in JAMA showing HSCT reversed neurologic disability and then over 5 years slowed or in most patients prevented further progressive disability or evidence of new disease activity in relapsing-remitting multiple sclerosis. (northwestern.edu)
  • Findings: Between Dec 1, 2014, and July 1, 2019, 281 patients were included in the intention-to-treat analysis: 144 (51%) patients were assigned to the short treatment group and 137 (49%) to the extended treatment group. (amsterdamumc.org)
  • FINDINGS: Between Dec 1, 2014, and Aug 20, 2019, 606 patients were randomly assigned to the decitabine (n=303) or 3â +â 7 (n=303) group. (bvsalud.org)
  • Following an interim analysis which showed futility, the IDMC recommended on May 22, 2019, that the study continued as planned considering the risks and benefits for the patients participating in the study. (bvsalud.org)
Diagnosis3
  • The child was referred to us from Hingoli district, a place on the outskirts of Maharashtra where he had already received platelet transfusion due to the diagnosis of dengue and per rectal bleeding. (pediatriconcall.com)
  • Mesothelioma can be a devastating diagnosis for patients and their families, and the disease has a significant impact throughout Europe, which has the highest incidence rate of mesothelioma globally," said Stefania Vallone, board member, Women Against Lung Cancer in Europe. (pharmiweb.com)
  • In all patients that might become considered for intensive treatment, the AML diagnosis should be based on morphologic and immunophenotypic features of bone marrow aspirates as well as on genetic characteristics of the leukemic blasts. (cancercentrum.se)
20201
  • 3 , 4 Since 2020, older or unfit patients are treated by a non-intensive approach combining the hypomethylating agent azacitidine and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax given orally until progression. (dovepress.com)
Survival11
  • The studies measured the percentage of participants who were still alive 100 days after HSCT (overall survival). (wikipedia.org)
  • Based on published reports and analyses of participant-level data, the expected survival rates 100 days after HSCT would be 21 to 31 percent for participants with severe hepatic VOD who received only supportive care or interventions other than defibrotide. (wikipedia.org)
  • OSAKA, Japan & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Takeda ( TSE:4502/NYSE:TAK ) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo. (businesswire.com)
  • KEYTRUDA, Merck's anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma (HCC) who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) compared with placebo plus best supportive care. (merck.com)
  • 1-3 Current treatment cures only a minority of AML patients and less than 20% have a long-term survival. (dovepress.com)
  • Although the impact of FLT3 -ITD mutation is unclear in the context of venetoclax-azacitidine treatment, 6 the negative impact of FLT3 -ITD on survival of AML patients treated with ICT is well established. (dovepress.com)
  • 1 , 7-9 In the 2017 European Leukemia network (ELN) classification, prognosis of FLT3 -ITD mutation on the survival of AML patients was dependent on the co-occurrence of the nucleophosmin 1 gene mutation ( NPM1 mut) and the FLT3 -ITD mutation burden. (dovepress.com)
  • This method multiplies the survival opportunity of the patient. (researchdive.com)
  • Patients with non-malignancy-associated HLH do not have better survival, although their prognosis is relatively better in clinical practice. (biomedcentral.com)
  • We retrospectively reviewed patients with malignancy- and non-malignancy-associated HLH at our institution and compared the clinical characteristics, treatment response, overall survival time, and prognostic factors of the two groups. (biomedcentral.com)
  • With the European Commission approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease. (pharmiweb.com)
Complications2
  • The study enrolled 413 patients who were randomized to receive either KEYTRUDA (200 mg fixed dose every three weeks for up to 35 cycles of treatment [up to approximately two years]) plus best supportive care (including pain management and management of other potential complications including ascites per local standards of care) or placebo plus best supportive care. (merck.com)
  • There are complications of serial transfusions of either of these cell types, and a patient needs intense prophylactic treatments to protect from infections if his or her white counts are low. (drugdiscoverynews.com)
Recipients3
  • The study found that rates of latent tuberculosis were 17% in all-HSCT recipients, 24% in auto-HSCT, and 39% in donors. (contagionlive.com)
  • To our knowledge, this is the first study that evaluates the prevalence of LTBI among HSCT recipients in a Latin American country where TB is endemic," the investigators wrote. (contagionlive.com)
  • In the section on aspergillosis, the revised recommendations include the use of a room with high-efficiency particulate air filters rather than laminar airflow as the protective environment for allogeneic HSCT recipients and the use of high-efficiency respiratory-protection devices (e.g. (cdc.gov)
Multiple sclerosis3
  • Over the last six months or so, there has been a wave of new and encouraging research published regarding HSCT (Hematopoietic Stem Cell Therapy) for the treatment of multiple sclerosis. (wheelchairkamikaze.com)
  • Because HSCT is directed entirely at replacing a patient's presumably defective immune system with a new one that doesn't attack the body's own nervous system cells, the prevailing thinking is that only patients displaying the hallmarks of immune system driven multiple sclerosis would likely respond well to the treatment. (wheelchairkamikaze.com)
  • Burt also conducted the first randomized HSCT trials for systemic sclerosis and multiple sclerosis, with strongly positive results. (northwestern.edu)
Hematological1
  • The Phase 3, randomized, double-blind, placebo-controlled, multicenter GRAPHITE study evaluated the efficacy and safety of vedolizumab as prophylaxis for intestinal aGvHD in patients undergoing allo-HSCT from unrelated donors for the treatment of hematological malignancies. (businesswire.com)
Infection5
  • The most common adverse reactions (reported in ≥20% of patients) are rash, infusion related reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection ( 6.1 ). (nih.gov)
  • do not give to patients with active infection and/or inflammatory disorders. (empr.com)
  • Withhold Clolar if a patient develops a clinically significant infection, until the infection is controlled, then restart at the full dose. (guidelinecentral.com)
  • 5. Patients with active infection, HIV-positive or chronic active HBV or HCV. (who.int)
  • However, the aim of treatment may be dependent on the genetic risk and comorbidity, and some patients may need supportive care for infection before being eligible for treatment decision. (cancercentrum.se)
Relapsed or refractory3
  • POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 ). (nih.gov)
  • POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. (nih.gov)
  • BACKGROUND: To ascertain the efficacy and safety of cladribine, cytarabine, and filgrastim-based regimen in relapsed or refractory (R/R) AML patients. (bvsalud.org)
Trials8
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • So far, two clinical trials of prophylaxis against invasive fungal infections were carried out with Noxafil oral suspension, which showed substantially fewer breakthrough infections caused by Aspergillus species in patients receiving posaconazole prophylaxis compared with patients receiving fluconazole or itraconazole. (pharmaceutical-technology.com)
  • and early trials resulted in vector-induced leukemia in 25% of patients due to insertion of the gene-carrying retrovirus near an oncogene. (stjude.org)
  • This accelerated approval was based on efficacy data from patients enrolled in one of five open-label, multi-cohort trials, including KEYNOTE-158. (businesswire.com)
  • MRK ), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer. (streetinsider.com)
  • As a result, "there is a need for further randomized trials comparing [HSCT] with these newer medications. (medscape.com)
  • Several groups are conducting trials to determine whether cellular therapy could be the treatment of choice for poor graft function after HSCT. (drugdiscoverynews.com)
Radiotherapy1
  • Moreover, their regulation mentions that the treatment of the cancer patients who have contracted COVID-19 should be performed in the respiratory or intensive care units instead of the oncology or radiotherapy units. (researchdive.com)
Therapy20
  • The median time from tositumomab/iodine-131tositumomab therapy to HSCT was 554 days (range: 77-2,893 days). (cancernetwork.com)
  • As monotherapy in second-line HCC, in addition to KEYNOTE-240 and KEYNOTE-224, KEYTRUDA is being investigated in the ongoing Phase 3, KEYNOTE-394 trial, a randomized, double-blind trial evaluating KEYTRUDA in combination with best supportive care, compared to placebo in combination with best supportive care, in Asian patients with advanced HCC who were previously treated with systemic therapy. (merck.com)
  • ClinicalTrials.gov, NCT02702401 ) evaluating KEYTRUDA plus best supportive care compared to placebo plus best supportive care in patients with advanced HCC who were previously treated with systemic therapy. (merck.com)
  • A 78-year-old woman with lung adenocarcinoma and multiple bone metastases received maintenance therapy with pemetrexed + pembrolizumab for a year. (journaltocs.ac.uk)
  • The patient received liver support therapy, and the serum hepatic enzymes recovered to normal levels. (journaltocs.ac.uk)
  • Now, more than 2 years after undergoing this new gene therapy, initial patients are producing a greater percentage of immune cells, including T, B and natural killer cells. (stjude.org)
  • Results for 8 patients under the age of 2 with XSCID in the second trial were presented at the 21st Annual Meeting of the American Society of Gene & Cell Therapy in May 2018. (stjude.org)
  • All infections resolved in the 3 patients who had disseminated infections prior to therapy. (stjude.org)
  • KEYNOTE-158 (ClinicalTrials.gov, NCT02628067 ) is an ongoing global, open-label, non-randomized, multi-cohort, multi-center, Phase 2 study evaluating KEYTRUDA in patients with multiple types of advanced solid tumors - including endometrial carcinoma - that have progressed on standard of care therapy. (businesswire.com)
  • PT/INR/aPTT ≤1.5 × ULN OR if patient is receiving anticoagulant therapy INR or aPTT is within target range of therapy. (mayo.edu)
  • Wheelchair Kamikaze: Recent Research on HSCT, the Stem Cell Therapy That May Soon Change the MS Treatment Landscape. (wheelchairkamikaze.com)
  • It's vitally important that patients not confuse HSCT with regenerative stem cell therapy, which attempts to directly repair the central nervous system damage done by MS. HSCT is a completely different approach with a completely different goal. (wheelchairkamikaze.com)
  • Regenerative stem cell therapy, such as that being trialed at the Tisch Center in New York ( click here ) generally does not involve any direct manipulation of patients' immune systems. (wheelchairkamikaze.com)
  • The European Society of Medical Oncology and National Health Service, England, has recommended a tiered method for classifying the patients into different priorities so that they can receive uninterrupted active cancer therapy during the pandemic. (researchdive.com)
  • No prior therapy has caused AQP4 to consistently disappear or allowed patients to become treatment free," said lead author Dr. Richard Burt, a professor of medicine and chief of immunotherapy and autoimmune disease at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician. (northwestern.edu)
  • He added that "there is an increasing use of high-efficacy treatment early in RRMS [relapsing-remitting MS], and this may make the subgroup with indication for HSCT as a rescue therapy smaller. (medscape.com)
  • We integrated 5 independent datasets totally 665 AML patients (497 CN-AML patients) to analyzed relation between NCALD gene expression and the clinical FAB classification, gene mutation, therapy, prognosis of CN-AML. (biomedcentral.com)
  • However, because secondary analyses suggested that serious adverse events and all-cause mortality occurred more often in patients who are persistantly febrile the short treatment group, we recommend vigilance for non-susceptible pathogens and early resumption of empirical therapy in patients who are deteriorating. (amsterdamumc.org)
  • We are pleased to see a new therapy approved that may offer patients and their families hope for a longer life. (pharmiweb.com)
  • CONCLUSION: The CLAG-related regimen is an effective and safe therapy for R/R AML patients, CLAG seems to have more superiority than CLAG combined therapy, though further studies including cladribine combination treatment protocols, are still needed to confirm our results further. (bvsalud.org)
Undergo2
  • T-cell immunity may also decrease over time, requiring 26% of patients to undergo a second HSCT. (stjude.org)
  • Incomplete engraftment (poor graft function) requires the patient to undergo more transfusions of red cells or platelets. (drugdiscoverynews.com)
Outcomes6
  • The model for improvement, which has demonstrated success in healthcare implementing practice changes with the goal of improving workflow and patient outcomes, took place over a 12-week period with a 7-step process of forming a team, setting aims, establishing measures, selecting changes, testing changes, implementing changes, and spreading changes. (oncnursingnews.com)
  • Although there is limited knowledge on caregiver experiences as well as needs, unplanned readmissions, medication errors, and adverse patient outcomes can be common issues during the discharge process. (oncnursingnews.com)
  • and varicella-zoster virus) can result in adverse patient outcomes and cause illness among health-care workers. (cdc.gov)
  • However, as the outcomes for patients with low- and intermediate-risk disease are similar, these categories have been collapsed into one and considered as low-risk disease. (nature.com)
  • The patients' clinical characteristics, treatment strategies and outcomes were retrospectively evaluated. (nih.gov)
  • A patient/population, intervention, comparison, and outcomes (PICO) framework was employed to ensure that the search strategies were structured and precise. (emerald.com)
Bone1
  • Patients with Philadelphia or BCR:ABL1 positive chronic myeloid leukaemia (CML) in blast phase defined by the presence of = 20% blasts in the blood or bone marrow who have achieved second chronic phase with (who.int)
Clinically2
  • According to the organization, higher priority should be given to patients with a life-threatening or clinically unstable condition. (researchdive.com)
  • Prophylactic transfusions with leukocyte-reduced platelet concentrates are used in patients at high risk of clinically significant hemorrhage. (medscape.com)
Undergone1
  • Changes [in the model] were selected based on direct feedback from parents who have already undergone the HSCT process and the multidisciplinary care team," the study authors wrote. (oncnursingnews.com)
Prognosis4
  • The expression level of NCALD gene is still unclear in the prognosis of patients with AML. (biomedcentral.com)
  • We analyzed the NCALD gene expression with the prognosis and LSC of 165 AML patients from The Cancer Genome Atlas (TCGA) dataset and 78 AML patients from GEO dataset. (biomedcentral.com)
  • NCALD can be considered as independent predictors of CN-AML patients and can be used as a biomarker for the prognosis of CN-AML. (biomedcentral.com)
  • The prognosis can be further stratified according to different gene mutation combinations in CN-AML patients. (biomedcentral.com)
Median age1
  • Among 161 patients (pts) included in the study, with a median age of 53 years (17-72), 98 pts (60.9%) received a reduced-intensity conditioning (RIC), 36 pts (22.4%) reduced-toxicity conditioning (RTC), 18 pts (11.1 %) sequential conditioning, and 9 pts (5.6%) myeloablative conditioning (MAC). (confex.com)
Participants2
  • In the three studies, 38 to 45 percent of participants treated with defibrotide were alive 100 days after HSCT. (wikipedia.org)
  • GRAPHITE (vedolizumab-3035) is a randomized, double-blind, placebo controlled study designed to evaluate the use of vedolizumab as prophylaxis of intestinal aGvHD in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder from an unrelated donor. (businesswire.com)
Prophylaxis1
  • Both tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, aged 13 and older, who are at high-risk of developing these infections due to being severely immunocompromised. (pharmaceutical-technology.com)
Donor4
  • Four patients were alive withno evidence of disease (three matched unrelated donor and one matched relateddonor). (cancernetwork.com)
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • The cells from the donor which are healthy are then infused into the sickle cell patient through a simple IV. (reachmd.com)
  • But unfortunately, only about 20% of patients with sickle cell disease in the United States have a matched donor. (reachmd.com)
Lymphoma1
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
Sickle cell di2
  • This essentially cures the patient of sickle cell disease. (reachmd.com)
  • Cystic fibrosis has received much more funding than sickle cell disease, and providers have reported in surveys that they do not feel comfortable with managing care for this disease. (managedhealthcareexecutive.com)
Malignant3
  • 1 HSCT is most commonly used as a treatment option for malignant conditions. (oncologynurseadvisor.com)
  • After many years of limited progress in the treatment of malignant mesothelioma, we saw an important clinical benefit for patients with nivolumab plus ipilimumab in the CheckMate -743 trial," said Paul Baas, M.D., Ph.D., Department of Thoracic Oncology, Netherlands Cancer Institute and the University of Leiden. (pharmiweb.com)
  • The European Commission's approval of Opdivo plus Yervoy is a crucial step in addressing the unmet needs of patients with malignant pleural mesothelioma. (pharmiweb.com)
Therapeutics1
  • Pluristem Therapeutics, based in Haifa, Israel, is currently recruiting patients in the United States and Israel for its Phase 1 trial of PLX-R18 cells in this unmet need. (drugdiscoverynews.com)
Investigators3
  • We sincerely thank the patients and investigators for their participation in this study and are committed to helping patients diagnosed with this common and difficult-to-treat type of liver cancer. (merck.com)
  • We thank all the patients, their families and the investigators involved. (streetinsider.com)
  • We thank the patients and investigators involved in the CheckMate -743 trial, whose contributions were essential to bringing the first immunotherapy option to mesothelioma patients throughout the EU. (pharmiweb.com)
Multidisciplinary1
  • A large number of HSCT patients require long-term follow-up from a multidisciplinary team, including rehabilitation specialists. (emerald.com)
Cancers1
  • 1 Intestinal aGvHD is a serious complication characterized by inflammation of the GI tract which can affect patients undergoing allo-HSCT, a common treatment for blood cancers. (businesswire.com)
Regimen2
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
  • Our main objective was to report our single-center experience with the DNA-hypomethylating agent, decitabine-combined minimally myelosuppressive regimen (DAC + MMR) bridged allo-HSCT in children with MDS. (nih.gov)
Unmet1
  • Thus, there is an unmet need for additional treatment options for these patients. (drugdiscoverynews.com)
Mortality1
  • The increasing rate of mortality and morbidity of the cancer patients who are being diagnosed with the novel virus has surged the demand for cancer stem cell treatment processes to be enhanced. (researchdive.com)
Adults3
  • ACIP recommendations specify the use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥65 years and for adults aged 19-64 years with certain underlying medical conditions or other risk factors who have not received a PCV or whose vaccination history is unknown. (cdc.gov)
  • In addition, ACIP recommends use of either a single dose of PCV20 or ≥1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses. (cdc.gov)
  • Updated and new clinical guidance for implementation from CDC includes the recommendation for use of PCV15 or PCV20 for adults who have received PPSV23 but have not received any PCV dose. (cdc.gov)
Graft1
  • Other groups are also working on cell therapies for the treatment of poor graft function after HSCT. (drugdiscoverynews.com)
Methods2
  • Recently, the U.S. Food and Drug Administration (FDA) has permitted GIOSTAR the urgent usage of stem cell methods to treat critical inflammation of the lungs in patients who are detected with COVID-19, under expanded access. (researchdive.com)
  • Methods: A cross-sectional study included 111 patients (age mean 56.2±10.6 years, 78.4% female, and disease duration mean 6 (3-13) years). (preprints.org)
20211
  • Since 11 October 2021, Australians who are severely immunocompromised have been able to receive a third COVID-19 vaccine dose as part of their primary vaccination course to increase their protection against COVID-19 to the highest level. (allergy.org.au)
Years11
  • Well, the reality is that most patients who are transplanted are younger, typically under age 16 years. (reachmd.com)
  • In the first trial, reported in the April 2016 issue of Science Translational Medicine , five males aged 10 to 23 years with progressively declining persistent immune dysfunction after parental HSCT in infancy were treated at the National Institute of Allergy and Infectious Diseases (NIAID). (stjude.org)
  • Two older patients demonstrated immune system reconstitution and clinical improvement at 2 to 3 years following treatment. (stjude.org)
  • KEYTRUDA monotherapy is already playing a role for the treatment of certain patients with advanced endometrial carcinoma through the tumor-agnostic MSI-H indication which received accelerated approval four years ago. (businesswire.com)
  • Furthermore, and perhaps even more astounding, there was a decrease in the disability scores in 50% of patients two years after treatment, and in 64% of patients four years after undergoing the treatment protocol without any further follow-up treatment ( click here ). (wheelchairkamikaze.com)
  • As a leader in lung cancer research, we continue to try to advance science for our patients by building upon the standard we set several years ago with KEYTRUDA," said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories. (streetinsider.com)
  • 14 years who had been diagnosed with HLH from January 2005 to October 2016 at the Children Medical Center of the Affiliated Hospital of Qingdao University were included and retrospectively reviewed after we had received University of Qingdao Ethics Committee approval. (biomedcentral.com)
  • Severe SCD shortens the life of a patient by 30 years on average. (managedhealthcareexecutive.com)
  • According to Bø, a 2017 study found that newer treatments bring up to 50% of patients to no evidence of disease activity at 2 years compared with 70%-90% for HSCT. (medscape.com)
  • Mesothelioma is often detected decades after exposure to asbestos, and for years these patients have faced this aggressive cancer with few treatment options. (pharmiweb.com)
  • In Sweden, 350 new adult patients are diagnosed per year - there are slightly more males than females and the ages range from 18 years of age to nonagenarians. (cancercentrum.se)
KEYTRUDA4
  • This positive EU CHMP opinion reinforces the potential of KEYTRUDA as a new option for patients with MSI-H/dMMR colorectal cancer and illustrates our ongoing commitment to pursuing biomarker research to help address the needs of patients who have few effective options. (merck.com)
  • KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma. (merck.com)
  • Cohort K enrolled 79 patients with MSI-H endometrial carcinoma and Cohort D enrolled 11 patients with MSI-H endometrial carcinoma for a total of 90 pooled patients who received KEYTRUDA as monotherapy (200 mg fixed dose every three weeks). (businesswire.com)
  • While these results are not what we hoped for, we are proud of the foundational role that KEYTRUDA has established in the treatment of certain types of lung cancer, and we are committed to continuing to research how we can further improve responses to our medicines for patients with difficult-to-treat forms of the disease. (streetinsider.com)
Adult patients1
  • The Committee also recommended granting a marketing authorisation for Cinqaero (reslizumab) as an add-on treatment for adult patients with severe eosinophilic asthma. (europa.eu)
Severely immunocompromised patients1
  • N95 respirators) by severely immunocompromised patients when they leave their rooms when dust-generating activities are ongoing in the facility. (cdc.gov)
Adverse2
  • Treatment-related adverse events were reported in 24.8% versus 28.4%, and treatment related serious adverse events in 8.5% versus 6.5% of patients treated with placebo versus vedolizumab, respectively. (businesswire.com)
  • Rates of grade 3-5 adverse events were 254 (84%) of 302 patients in the decitabine group and 279 (94%) of 298 patients in the 3â +â 7 group. (bvsalud.org)
Implications1
  • So that this article doesn't take on the length of a Russian novel, rather than getting into the detailed specifics of what HSCT is and isn't I'd like to concentrate on the recent HSCT published research and its implications. (wheelchairkamikaze.com)
Stem cells1
  • Government bodies and healthcare experts around the world are making investments in research & development in the industry in order to enhance the profitability of cancer stem cells in the treatment of cancer patients. (researchdive.com)
Disease4
  • The health-care facility environment is rarely implicated in disease transmission, except among patients who are immunocompromised. (cdc.gov)
  • The Committee recommended that Adempas (riociguat) should not be used in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia or PH-IIP (high blood pressure in lung arteries caused by a lung disease called idiopathic interstitial pneumonia). (europa.eu)
  • Not only did the vast majority of these patients see their disease stop in its tracks, but a large proportion also saw their levels of disability improve. (wheelchairkamikaze.com)
  • When treatment options are limited, it is likely to have a good effect in younger patients with a shorter disease duration and a low disability. (medscape.com)
Malignancy3
  • The patients were divided into the malignancy-associated group ( n = 22) and non-malignancy-associated group ( n = 69, also considered the control group). (biomedcentral.com)
  • In this study, we also share our limited experiences with allogeneic HSCT in malignancy-associated HLH. (biomedcentral.com)
  • 6. Patients with a concurrent active malignancy or a prior malignancy, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of the skin or treated cervical carcinoma in situ, an incidental histologic finding of prostate cancer (T1a or T1b using the tumour, node, metastasis (TNM) clinical staging system), previous MDS, CMML, MPN resulting in secondary AML. (who.int)